Post by
Gbathat on Mar 24, 2021 10:05am
not much pps movement
I'm surprised the pps has not gotten much of a boost from the recent news. I guess the headline is financing-focused. Hopefully the actions mentioned further down in the PR become their own PRs soon.
If I recall, their number for PHI was $10M. Perhaps there will be a 50-50 JV with a larger company in the pipe, at $5M a piece. I think a partnership with a trusted 'big' from pharma would go a long way in building investor confidence. The comments about DD by the new investors were definitely encouraging in the meantime.
There is no reason to go it alone on the PMN310 venture. Profits would be huge for a small company no matter how you slice the final product, and the underlying objective of treating Alz is just too important to wait. PMN also has lots of other products in the pipeline.
I am very excited about the future here. So much potential.
Comment by
M101 on Mar 24, 2021 1:10pm
Wait for the warrant financiers to unload the remaining shares they never wanted and for the company to make a stronger statement on clinical testing. That will take longer than the Aducanumab decision.